Organization
Kyungpook National University Chilgok Hospital
1 clinical trial
5 abstracts
Abstract
Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR+) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04.Org: Memorial Sloan Kettering Cancer Center, Kanagawa Cancer Center, Severance Hospital, Hospital Clinic de Barcelona, Barcelona, Spain, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
Ten-year outcomes of targeted axillary surgery after neoadjuvant chemotherapy in breast cancer.Org: Kyungpook National University Hospital, Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV, Kyungpook National University School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital,
Abstract
Prognostic significance of ctDNA mutation analysis in patients with HER2-positive breast cancer undergoing neoadjuvant chemotherapy.Org: Kyungpook National University Chilgok Hospital, Kyungpook National University, Predicine, Inc., Hayward, CanSino Biologics,
Clinical trial
Optimal Concentration of Remifentanil for Achieving Excellent Intubating Condition During Low-dose Neuromuscular Blocking Agent Administration for Intraoperative Neuromonitoring Using Nerve Integrity Monitoring TubeStatus: Recruiting, Estimated PCD: 2024-03-20
Abstract
Omission of breast surgery for predicted pCR patients with MRI and vacuum-assisted biopsy in breast cancer after neoadjuvant chemotherapy: A multicenter, single-arm, non-inferiority trial (OPTIMIST trial).Org: Department of Surgery, Brigham and Women's Hospital, Boston, MA, Seoul National University College of Medicine, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Seoul National University Hospital, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
Abstract
Use of tumoral LDH to predict residual tumor burden after neoadjuvant chemotherapy in breast cancer.Org: Kyungpook National University Chilgok Hospital, Kyungpook National University, Kyungpook National University Hospital, Department of Pathology, Kyungpook National University School of Medicine,